GW280264X

capable of blocking tumor necrosis factor-alpha-converting enzyme (TACE) and the closely related disintegrin-like metalloproteinase 10 (ADAM10)

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 04/23/2021 - "Finally, we found an improved effect of GW280264X with cisplatin in tumor spheroids derived from patient samples. " 10/16/2019 - "Primary HUVEC were irradiated with 2 or 4 Gy photons at a dose rate of 5 Gy/min. The permeability of an irradiated endothelial monolayer for macromolecules and tumor cells was analyzed in the presence or absence of the ADAM10/17 inhibitors GI254023X and GW280264X. "
2.	Ovarian Neoplasms (Ovarian Cancer) 04/23/2021 - "Here, we tested the effect of the ADAM17 inhibitor GW280264X in combination with cisplatin on ovarian cancer cells in 2D and 3D. "
3.	Adenocarcinoma of Lung 01/01/2020 - "CRISPR-driven and inhibitor-based (GW280264X, and ADAM17 prodomain) ADAM17 targeting was employed in the human lung adenocarcinoma cell lines A549 and NCI-H23. "

1.	Cisplatin (Platino)
2.	3- (formylhydroxyamino)- 2- (3- phenyl- 1- propyl)butanoic acid (2,2- dimethyl- 1- methylcarbamoyl- 1- propyl)amide